Ototoxic Monitoring of 4000 Hz threshold in a Pediatric Population Diagnosed with Germ Cell Tumors in a Compressed Cisplatin Chemotherapy Trial
Product Description:
• Germ cell tumor management commonly
includes surgery and chemotherapy with
cisplatin1
• 15% of patients treated with standard
therapy (400mg/m2 cisplatin) develop
hearing loss2
• Risk factors for cisplatin induced hearing loss:
• Younger age (~<5 years) 2
• Higher fraction dosage2
• International guidelines recommend hearing
monitoring before, during, and after treatment3
Compressed Chemotherapy Regime
Keyword(s):
Germcell tumors, Chemotherapy, Ototoxic
Product/Publication Type(s):
Conference presentations and posters presented
Target Audience:
Professionals, Students
Alternative Format:
Visual Format or Large Print
To Obtain Copies (URL or Email):
COVID-19 Related Data:
N/A